InvestorsObserver is giving Ovid Therapeutics Inc (OVID) an Analyst Rating Rank of 29, meaning OVID is ranked higher by analysts than 29% of stocks. The average price target for OVID is $5 and analyst’s rate the stock as a Buy.
Wall Street analysts are rating OVID a Buy today. Find out what this means to you and get the rest of the rankings on OVID!